Izpisua Belmonte, PhD, Altos Labs, advocates a disease-agnostic approach, but first, he said, “we must understand the mechanism, something that is core to the cell.” ...

System MarketThe global Mesenchymal Stem Cells Market is valued at USD 3.82 Billion in 2024 and is projected to reach a value of USD 9.08 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...

Mesoblast (MESO) “announced gross revenue of $21.9 million on Ryoncil (remestemcel-L-rknd) sales for the quarter ended September 30, 2025. This ...

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company ...

The MSC market offers significant opportunities in regenerative medicine, cosmeceuticals, and cultured meat production. Leveraging their regenerative and immuno-evasive properties, MSCs are key in ...

The new permanent J-Code, J3402, provides a standardized, clear, permanent, and specific billing pathway for Ryoncil ® by Medicaid, facilitating reimbursement and broader patient access for this ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Mesoblast Limited is one of them.

Abstract: Electrochemical impedance spectroscopy (EIS), serving as an invasive yet insightful diagnostic method, unveils a trove of status information and has been utilized in data-driven state ...

Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast Limited announced that its allogeneic cell therapy products, manufactured ...

Ryoncil® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company’s Biologic License ...

The product is sonruvetcel suspension for injection – a potential first-in-class, uterine-derived allogeneic mesenchymal stromal cell therapy for cats with refractory feline ...